Dolby Laboratories Financial Statements (DLB)
|
|
|
|
Report date
|
|
|
01.05.2025 |
31.07.2025 |
18.11.2025 |
29.01.2026 |
30.04.2026 |
|
30.04.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
369.6 |
315.5 |
307.0 |
346.7 |
395.6 |
|
1 365 |
|
Operating Income, bln rub |
|
|
112.0 |
47.6 |
29.7 |
62.2 |
115.1 |
|
254.6 |
|
EBITDA, bln rub |
? |
|
136.4 |
71.5 |
60.4 |
102.5 |
142.0 |
|
376.4 |
|
Net profit, bln rub |
? |
|
91.8 |
46.1 |
49.3 |
53.3 |
94.9 |
|
243.6 |
|
|
OCF, bln rub |
? |
|
174.9 |
67.7 |
122.8 |
54.8 |
92.5 |
|
337.8 |
|
CAPEX, bln rub |
? |
|
6.90 |
6.43 |
21.8 |
5.38 |
9.06 |
|
42.7 |
|
FCF, bln rub |
? |
|
168.0 |
61.3 |
101.0 |
49.4 |
83.4 |
|
295.1 |
|
Dividend payout, bln rub
|
|
|
31.8 |
31.6 |
31.6 |
34.3 |
34.3 |
|
131.9 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
34.7% |
68.7% |
64.0% |
64.4% |
36.2% |
|
54.1% |
|
|
OPEX, bln rub |
|
|
221.8 |
223.9 |
237.8 |
241.3 |
235.8 |
|
938.8 |
|
Cost of production, bln rub |
|
|
35.8 |
44.0 |
39.5 |
43.2 |
44.7 |
|
171.5 |
|
R&D, bln rub |
|
|
61.7 |
66.0 |
67.5 |
69.1 |
63.7 |
|
266.2 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.000 |
0.000 |
4.12 |
0.000 |
|
4.12 |
|
|
Assets, bln rub |
|
|
3 229 |
3 196 |
3 228 |
3 192 |
3 249 |
|
3 249 |
|
Net Assets, bln rub |
? |
|
2 574 |
2 605 |
2 623 |
2 594 |
2 618 |
|
2 618 |
|
Debt, bln rub |
|
|
40.4 |
39.1 |
38.9 |
40.6 |
49.7 |
|
49.7 |
|
Cash, bln rub |
|
|
750.3 |
699.3 |
702.6 |
644.6 |
594.7 |
|
594.7 |
|
Net debt, bln rub |
|
|
-709.9 |
-660.2 |
-663.7 |
-603.9 |
-545.1 |
|
-545.1 |
|
|
Ordinary share price, rub |
|
|
79.9 |
74.1 |
72.4 |
65.7 |
58.0 |
|
58.0 |
|
Number of ordinary shares, mln |
|
|
96.3 |
95.9 |
95.6 |
95.5 |
95.2 |
|
95.2 |
|
|
Market cap, bln rub |
|
|
7 698 |
7 101 |
6 923 |
6 273 |
5 526 |
|
5 526 |
|
EV, bln rub |
? |
|
6 988 |
6 441 |
6 259 |
5 669 |
4 980 |
|
4 980 |
|
Book value, bln rub |
|
|
1 637 |
1 668 |
1 696 |
1 699 |
1 699 |
|
1 699 |
|
|
EPS, rub |
? |
|
0.95 |
0.48 |
0.52 |
0.56 |
1.00 |
|
2.56 |
|
FCF/share, rub |
|
|
1.74 |
0.64 |
1.06 |
0.52 |
0.88 |
|
3.10 |
|
BV/share, rub |
|
|
17.0 |
17.4 |
17.7 |
17.8 |
17.8 |
|
17.8 |
|
|
EBITDA margin, % |
? |
|
36.9% |
22.7% |
19.7% |
29.6% |
35.9% |
|
27.6% |
|
Net margin, % |
? |
|
24.8% |
14.6% |
16.1% |
15.4% |
24.0% |
|
17.9% |
|
FCF yield, % |
? |
|
5.07% |
6.17% |
6.22% |
6.05% |
5.34% |
|
5.34% |
|
ROE, % |
? |
|
9.97% |
10.1% |
9.72% |
9.27% |
9.31% |
|
9.31% |
|
ROA, % |
? |
|
7.95% |
8.27% |
7.90% |
7.53% |
7.50% |
|
7.50% |
|
|
P/E |
? |
|
30.0 |
26.9 |
27.1 |
26.1 |
22.7 |
|
22.7 |
|
P/FCF |
|
|
19.7 |
16.2 |
16.1 |
16.5 |
18.7 |
|
18.7 |
|
P/S |
? |
|
5.83 |
5.27 |
5.13 |
4.69 |
4.05 |
|
4.05 |
|
P/BV |
? |
|
4.70 |
4.26 |
4.08 |
3.69 |
3.25 |
|
3.25 |
|
EV/EBITDA |
? |
|
17.4 |
16.0 |
16.5 |
15.3 |
13.2 |
|
13.2 |
|
Debt/EBITDA |
|
|
-1.77 |
-1.64 |
-1.75 |
-1.63 |
-1.45 |
|
-1.45 |
|
|
R&D/CAPEX, % |
|
|
894.7% |
1 026% |
308.9% |
1 284% |
702.4% |
|
623.3% |
|
|
CAPEX/Revenue, % |
|
|
1.87% |
2.04% |
7.11% |
1.55% |
2.29% |
|
3.13% |
|
| Dolby Laboratories shareholders |
